Treeline and Roche collaborate on TLN-121 combo trial for BCL

PartnershipTLN-121glofitamabmosunetuzumabPositive

AI Analysis

Summary

Treeline Biosciences and Roche entered into a clinical trial collaboration and supply agreement for a Phase 1 study evaluating Treeline's BCL6 degrader TLN-121 combined with Roche's CD20×CD3 bispecific antibodies glofitamab and mosunetuzumab in B-cell lymphoma patients.

Clinical Trial Data

Phase

Phase 1

Importance:6/10

Sentiment:

0.50

clinical collaborationcombination therapyoncologyB-cell lymphomaBCL6 degraderbispecific antibody

Related Companies

$TRAX $RHHBY

Read the original article

Published by Clinical Trials Arena on September 3, 2026 9:38 AM

Read Original